PE20001644A1 - Composicion de un derivado de (5-aril-1,2,4-tiadiazol)-3-il tiourea o un derivado de (5-aril-1,2,4-tiadiazol)-3-il urea para tratar infecciones virales - Google Patents
Composicion de un derivado de (5-aril-1,2,4-tiadiazol)-3-il tiourea o un derivado de (5-aril-1,2,4-tiadiazol)-3-il urea para tratar infecciones viralesInfo
- Publication number
- PE20001644A1 PE20001644A1 PE2000000287A PE0002872000A PE20001644A1 PE 20001644 A1 PE20001644 A1 PE 20001644A1 PE 2000000287 A PE2000000287 A PE 2000000287A PE 0002872000 A PE0002872000 A PE 0002872000A PE 20001644 A1 PE20001644 A1 PE 20001644A1
- Authority
- PE
- Peru
- Prior art keywords
- derivative
- aryl
- composition
- thadiazole
- thiourea
- Prior art date
Links
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 title abstract 4
- 208000036142 Viral infection Diseases 0.000 title abstract 2
- 239000004202 carbamide Substances 0.000 title abstract 2
- 239000000725 suspension Substances 0.000 abstract 2
- 229920001817 Agar Polymers 0.000 abstract 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
- 239000001828 Gelatine Substances 0.000 abstract 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 abstract 1
- -1 SUCROSA Substances 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000008272 agar Substances 0.000 abstract 1
- 230000001476 alcoholic effect Effects 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 abstract 1
- 229920000159 gelatin Polymers 0.000 abstract 1
- 235000019322 gelatine Nutrition 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 abstract 1
- 229960001627 lamivudine Drugs 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UNA COMPOSICION QUE CONTIENE: a)1 mg/kg A 10000 mg/kg DE UN DERIVADO DE (5-ARIL-1,2,4-TIADIAZOL)-3-IL TIOUREA, O UN DERIVADO DE (5-ARIL-1,2,4-TIADIAZOL)-3-IL UREA DE FORMULA I, DONDE X: ES O, S; R ES H, ALQUILO C1-C3; n ES 0-4; R1 ES H, ALQUILO C1-C7, Cl, Br, F, OXICLORO, ALCOXI O(CH2)y(CH3); y ES 1-6 O SU SAL DE ADICION ACIDAS TAL COMO CLORUROS, BROMUROS, SULFATOS, NITRATOS, ENTRE OTROS; b)UNA TERAPIA COMBINADA CON AZIDOVUDINA (AZT), LAMIVUDINA (TC-3), INHIBIDORES DE PROTEASA. LA COMPOSICION SE PRESENTA EN FORMA SOLIDA QUE INCLUYE COMO PORTADOR LACTOSA, SUCROSA, GELATINA, AGAR; EN FORMA LIQUIDA INCLUYE SOLUCIONES ACUOSAS, SOLUCIONES ALCOHOLICAS, SUSPENSIONES, SUSPENSIONES RECONSTITUIDAS, ENTRE OTROS. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE INFECCIONES VIRALES COMO VIH, HERPES, HEPATITIS C
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28189699A | 1999-03-31 | 1999-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20001644A1 true PE20001644A1 (es) | 2001-02-06 |
Family
ID=23079226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000000287A PE20001644A1 (es) | 1999-03-31 | 2000-03-31 | Composicion de un derivado de (5-aril-1,2,4-tiadiazol)-3-il tiourea o un derivado de (5-aril-1,2,4-tiadiazol)-3-il urea para tratar infecciones virales |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6258831B1 (es) |
| EP (1) | EP1165070B1 (es) |
| JP (1) | JP2002540156A (es) |
| AR (1) | AR019505A1 (es) |
| AT (1) | ATE297729T1 (es) |
| AU (1) | AU763573B2 (es) |
| CA (1) | CA2368615C (es) |
| CO (1) | CO5160294A1 (es) |
| DE (1) | DE60020820T2 (es) |
| PE (1) | PE20001644A1 (es) |
| WO (1) | WO2000057878A1 (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6423695B1 (en) * | 1998-01-13 | 2002-07-23 | Ribapharm, Inc. | Cytokine related treatments of disease |
| US6245788B1 (en) * | 1999-03-31 | 2001-06-12 | The Procter & Gamble Company | Viral treatment |
| DE10120627A1 (de) * | 2001-04-26 | 2002-10-31 | Cmi Ag | Verwendung von Phyllanthusbestandteilen zur Behandlung oder Prophylaxe von Infekten durch Hepatitis B-Viren |
| US20050239054A1 (en) * | 2002-04-26 | 2005-10-27 | Arimilli Murty N | Method and compositions for identifying anti-HIV therapeutic compounds |
| DK1509537T3 (da) | 2002-04-26 | 2007-11-12 | Gilead Sciences Inc | Cellulær akkumulering af phosphonatanaloger af HIV-protease-inhibitorforbindelser og forbindelserne som sådanne |
| US20040010036A1 (en) * | 2002-05-07 | 2004-01-15 | Boris Rogovoy | N,N, -Substituted s-Aryl-Isothioureas, N,N,N, -Substituted s-Aryl-Isothioureas and combinatorial libraries thereof |
| AU2003282883B2 (en) * | 2002-11-18 | 2008-12-04 | Polaris Group | Methods for inhibiting viral replication in vivo |
| US20040175384A1 (en) * | 2003-12-12 | 2004-09-09 | Mohapatra Shyam S. | Protein kinase C as a target for the treatment of respiratory syncytial virus |
| US7470724B2 (en) * | 2003-04-25 | 2008-12-30 | Gilead Sciences, Inc. | Phosphonate compounds having immuno-modulatory activity |
| WO2004096234A2 (en) * | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Kinase inhibitor phosphonate conjugates |
| US7407965B2 (en) | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
| US7452901B2 (en) * | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
| WO2004096287A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds |
| WO2005002626A2 (en) * | 2003-04-25 | 2005-01-13 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
| PL1628685T3 (pl) | 2003-04-25 | 2011-05-31 | Gilead Sciences Inc | Przeciwwirusowe analogi fosfonianowe |
| WO2004096285A2 (en) * | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Anti-infective phosphonate conjugates |
| US20050261237A1 (en) * | 2003-04-25 | 2005-11-24 | Boojamra Constantine G | Nucleoside phosphonate analogs |
| US7432261B2 (en) * | 2003-04-25 | 2008-10-07 | Gilead Sciences, Inc. | Anti-inflammatory phosphonate compounds |
| CN101410120A (zh) * | 2003-04-25 | 2009-04-15 | 吉里德科学公司 | 抗炎的膦酸酯化合物 |
| WO2005044308A1 (en) | 2003-10-24 | 2005-05-19 | Gilead Sciences, Inc. | Phosphonate analogs of antimetabolites |
| CA2543142A1 (en) | 2003-10-24 | 2005-05-12 | Gilead Sciences, Inc. | Methods and compositions for identifying therapeutic compounds |
| WO2005044279A1 (en) | 2003-10-24 | 2005-05-19 | Gilead Sciences, Inc. | Purine nucleoside phosphonate conjugates |
| US7253175B2 (en) * | 2003-11-13 | 2007-08-07 | Barnet Liberman | Method for treating athlete's foot |
| US8592368B2 (en) | 2003-12-19 | 2013-11-26 | University Of South Florida | JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection |
| BRPI0418031A (pt) * | 2003-12-22 | 2007-04-17 | Gilead Sciences Inc | inibidores de quinase fosfonato-substituìdos |
| EP1706405B1 (en) | 2003-12-22 | 2009-03-04 | Gilead Sciences, Inc. | 4'-substituted carbovir- and abacavir-derivatives as well as related compounds with hiv and hcv antiviral activity |
| US20050153990A1 (en) * | 2003-12-22 | 2005-07-14 | Watkins William J. | Phosphonate substituted kinase inhibitors |
| TW200600492A (en) * | 2004-05-18 | 2006-01-01 | Achillion Pharmaceuticals Inc | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication |
| US8318701B2 (en) | 2004-07-27 | 2012-11-27 | Gilead Sciences, Inc. | Phosphonate analogs of HIV inhibitor compounds |
| US20060264422A1 (en) * | 2005-05-09 | 2006-11-23 | Johannes Reinmueller | Use of taurolidine as enhancer of the complement system |
| JP2009510122A (ja) * | 2005-09-29 | 2009-03-12 | ザ スクリプス リサーチ インスティテュート | ウイルスペプチドおよびフラビウイルス科のウイルスに対してウイルス感染を阻害するためのその使用 |
| US7480400B2 (en) * | 2006-03-16 | 2009-01-20 | Siemens Medical Solutions Usa, Inc. | Detection of fiber pathways |
| EA018308B1 (ru) * | 2008-07-08 | 2013-07-30 | Джилид Сайэнс, Инк. | Соли соединений ингибиторов вич |
| ES2892402T3 (es) | 2017-08-01 | 2022-02-04 | Gilead Sciences Inc | Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales |
| KR20210046649A (ko) * | 2018-08-21 | 2021-04-28 | 교린 세이야꾸 가부시키 가이샤 | 이환식 헤테로방향환 유도체 |
| CN112245570A (zh) * | 2019-07-22 | 2021-01-22 | 厦门特宝生物工程股份有限公司 | 一种基于干扰素的疾病治疗方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4353920A (en) * | 1980-08-25 | 1982-10-12 | Olin Corporation | Use of selected 3-trihalomethyl-5-ureido-1,2,4-oxadiazoles and -1,2,4-thiadiazoles as agricultural viricides |
| JPS57136579A (en) * | 1981-01-21 | 1982-08-23 | Mitsui Toatsu Chem Inc | Thiazolylurea derivative, its preparation, and pharmaceutical composition containing the same |
| US4835168A (en) * | 1985-12-16 | 1989-05-30 | Eli Lilly And Company | Thiadiazole antiviral agents |
| US5256680A (en) * | 1988-11-29 | 1993-10-26 | Warner-Lambert Company | 3,5-di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxy-phenyl-1,2,4-thiadazoles, oxadiazoles and triazoles as antiinflammatory agents |
| US5593993A (en) | 1991-08-02 | 1997-01-14 | Medivir Ab | Method for inhibition of HIV related viruses |
| IL102548A (en) | 1991-08-02 | 1998-08-16 | Medivir Ab | Thiourea derivatives for use in the preparation of medicaments for the inhibition of hiv and the treatment of aids and some such novel compounds |
| JPH07149748A (ja) * | 1993-09-30 | 1995-06-13 | Souyaku Gijutsu Kenkyusho:Kk | チアジアゾール誘導体及びその製造法 |
| JPH08169881A (ja) * | 1994-09-22 | 1996-07-02 | Soyaku Gijutsu Kenkyusho:Kk | アリールチアジアゾール誘導体及びそれを含有する抗ウイルス剤 |
| JPH08245384A (ja) * | 1995-03-13 | 1996-09-24 | Soyaku Gijutsu Kenkyusho:Kk | 抗ウイルス剤 |
| US6162791A (en) | 1998-03-02 | 2000-12-19 | Apotex Inc. | Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes |
-
2000
- 2000-03-27 US US09/535,172 patent/US6258831B1/en not_active Expired - Fee Related
- 2000-03-29 DE DE60020820T patent/DE60020820T2/de not_active Expired - Lifetime
- 2000-03-29 JP JP2000607629A patent/JP2002540156A/ja active Pending
- 2000-03-29 WO PCT/US2000/008421 patent/WO2000057878A1/en not_active Ceased
- 2000-03-29 CA CA002368615A patent/CA2368615C/en not_active Expired - Fee Related
- 2000-03-29 AU AU41822/00A patent/AU763573B2/en not_active Ceased
- 2000-03-29 AT AT00921515T patent/ATE297729T1/de not_active IP Right Cessation
- 2000-03-29 EP EP00921515A patent/EP1165070B1/en not_active Expired - Lifetime
- 2000-03-31 AR ARP000101499A patent/AR019505A1/es not_active Application Discontinuation
- 2000-03-31 CO CO00023489A patent/CO5160294A1/es unknown
- 2000-03-31 PE PE2000000287A patent/PE20001644A1/es not_active Application Discontinuation
-
2001
- 2001-03-19 US US09/812,094 patent/US6410575B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2368615A1 (en) | 2000-10-05 |
| US6410575B2 (en) | 2002-06-25 |
| EP1165070B1 (en) | 2005-06-15 |
| WO2000057878A1 (en) | 2000-10-05 |
| ATE297729T1 (de) | 2005-07-15 |
| AU4182200A (en) | 2000-10-16 |
| AR019505A1 (es) | 2002-02-20 |
| EP1165070A1 (en) | 2002-01-02 |
| JP2002540156A (ja) | 2002-11-26 |
| AU763573B2 (en) | 2003-07-24 |
| CA2368615C (en) | 2007-01-02 |
| US20010031773A1 (en) | 2001-10-18 |
| CO5160294A1 (es) | 2002-05-30 |
| DE60020820T2 (de) | 2006-05-04 |
| US6258831B1 (en) | 2001-07-10 |
| DE60020820D1 (de) | 2005-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20001644A1 (es) | Composicion de un derivado de (5-aril-1,2,4-tiadiazol)-3-il tiourea o un derivado de (5-aril-1,2,4-tiadiazol)-3-il urea para tratar infecciones virales | |
| RU2004110719A (ru) | Зздабиторы протеаз, расщепляющих за пролином | |
| PE20020050A1 (es) | Composicion farmaceutica liquida que contiene eritropoyetina y un anion inorganico | |
| HRP20050663A2 (en) | Malonamide derivatives as gamma-secretase inhibitors | |
| BR8003248A (pt) | Processo de preparacao de composicao de branqueamento espessa aquosa | |
| KR890000098A (ko) | 세포 및 조직 수복제 | |
| NZ597544A (en) | Modified 4'-nucleosides as antiviral agents | |
| EA200000594A1 (ru) | Новые макролиды | |
| PE20070210A1 (es) | Compuestos macrociclicos como inhibidores del virus de hepatitis c | |
| CL2004002061A1 (es) | Compuestos derivados de heterociclos condensados que contienen nitrogeno; composicion farmaceutica; y su uso como agente antiviral, inhubidor de integrasa y como agente anti-vih. | |
| YU75403A (sh) | Vodeni amfotericin b preparat | |
| PE20020216A1 (es) | PRODROGAS 3' DE 2' -DESOXI-ß-L-NUCLEOSIDOS | |
| ES2063146T3 (es) | Composiciones farmaceuticas que contienen acido n-(3,4-dimetoxicinamoil)-antranilico. | |
| EA200401522A1 (ru) | Противотуберкулёзный препарат: композиции и способы | |
| NO20076219L (no) | Farmasoytisk formulering med apomorfin for bukkal administrering | |
| ECSP045469A (es) | El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas | |
| ES2146662T3 (es) | Aditivos para soluciones de grabado de cobre. | |
| AR002018A1 (es) | Derivado de benzotiepina opticamente activo; metodo para producirlo; compuesto opticamente activo de uso en dicho metodo; promotor deosteogenesis, agente para prevenir o tratar enfermedades del hueso, promotor para el tratamiento de la fractura de hueso, metodo de tratamiento y | |
| PE20061063A1 (es) | Derivados de taxanos como agentes citotoxicos | |
| WO2006062898A3 (en) | Compounds and methods for treating hemorrhagic fever viruses | |
| PE20050310A1 (es) | Derivados del acido 3-(1-[3-(1,3--benzotiazol-6-il)propilcarbamoil]cicloalquil)propanoico como inhibidores de nep | |
| PE20001608A1 (es) | Uso de (5-aril-1,2,4-tiadiazol)-3-il-urea o (5-aril-1,2,4-tiadiazol)-3-il-tiourea para tratar infecciones virales | |
| JPH02502913A (ja) | 無機塩類および酢酸を主成分とする、ウイルス性疾患の予防および治療用の水性製剤 | |
| TW200501940A (en) | Virus therapeutic drug | |
| ATE401901T1 (de) | Antikrebs- und antivirale zusammensetzung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |